279,932 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Cibc World Market Inc.

Cibc World Market Inc. purchased a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 279,932 shares of the company’s stock, valued at approximately $8,586,000.

Several other large investors have also made changes to their positions in the business. Osaic Holdings Inc. grew its position in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares in the last quarter. CWM LLC boosted its stake in Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares during the period. AlphaCore Capital LLC bought a new position in Genmab A/S in the 2nd quarter worth approximately $44,000. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 124.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after buying an additional 1,174 shares during the last quarter. Finally, Cromwell Holdings LLC lifted its holdings in shares of Genmab A/S by 136.3% in the third quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after buying an additional 883 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $30.03 on Friday. The firm has a market capitalization of $19.29 billion, a PE ratio of 12.78, a PEG ratio of 17.37 and a beta of 0.90. The stock’s fifty day moving average is $32.35 and its 200 day moving average is $29.66. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $35.43.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GMAB. Truist Financial reiterated a “buy” rating and issued a $48.00 price target (down from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Genmab A/S in a research note on Wednesday, January 28th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.33.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.